Biology marker for making diagnosis and giving treatment on abdominal aortic aneurysm

Abstract

The invention discloses a biology marker for making diagnosis and giving treatment on abdominal aortic aneurysm. The biology marker is OTUB2. QPCR experiments prove that the OTUB2 has difference expression in patients suffering from abdominal aortic aneurysm, in order to further verify the relevance of the OTUB2 and the abdominal aortic aneurysm, an AAA cell model is constructed, so that the viewpoint that interference of OTUB2 expression can reverse damage effects of Angiotensin II on cells can be proved, and the OTUB2 can be the biology marker for making diagnosis and giving treatment on abdominal aortic aneurysm. The research findings provide a new method and strategy for clinical diagnosis or treatment of the abdominal aortic aneurysm.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a biomarker for diagnosis and treatment of abdominal aortic aneurysm. Background technique [0002] Abdominal aortic aneurysm (AAA) is a localized and permanent expansion of the abdominal aorta that occurs mostly in middle-aged or elderly people. Compared with the adjacent abdominal aorta, it is more than 50% dilated or the A diameter greater than 3 cm is its diagnostic criterion. With the popularization of medical examination methods such as CT and MRI, the incidence of AAA has been increasing worldwide, and the incidence has increased by 7 times in the past 30 years, becoming one of the most common aortic diseases in clinical practice. my country currently lacks comprehensive epidemiological data on AAA. In the United States, the prevalence of AAA among people over 65 years old is 8%, ranking the No. 13 disease killer in the United States. However, due to the lack of timely diagnosis ...

AI Technical Summary

Problems solved by technology

AAA can be treated surgically (endovascular exclusion or aortic reconstruction) to reduce rupture mortality and improve prognosis, but there is no targeted medical treatment

Whether it is the previous traditional treatment method: laparotomy resection and artificial vascular grafting, or the interventional endovascular stent graft treatment that has developed rapidly in the past 15 years, there are relatively high surgical risks and huge overall treatment costs. A considerable proportion of patients cannot or are not suitable for surgical intervention due to heart, liver, brain, lung, kidney and other vital organ lesions

Images